119 related articles for article (PubMed ID: 38777703)
1. Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma.
Shao K; Hao Y; Xu M; Shi Z; Lin G; Xu C; Zhang Y; Song Z
Clin Oncol (R Coll Radiol); 2024 Apr; ():. PubMed ID: 38777703
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma.
Song Z
J Thorac Dis; 2014 Dec; 6(12):1808-12. PubMed ID: 25589977
[TBL] [Abstract][Full Text] [Related]
4. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
5. [Single-center study of different treatment for advanced or unresectable angiosarcoma patients].
Peng RQ; Xu BS; Liu YY; Yang QQ; Pan QZ; Zhang X
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):74-81. PubMed ID: 36709123
[No Abstract] [Full Text] [Related]
6. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety evaluation of immunotherapy combined with targeted therapy as second-line treatment in patients with metastatic non-clear cell renal cell carcinoma].
Wang J; Wei WS; Jiang LJ; Zhang ZL; Guo SJ; Han H; Zhou FJ; Dong P
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):704-708. PubMed ID: 37580277
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
Hirai F; Yamanaka T; Taguchi K; Daga H; Ono A; Tanaka K; Kogure Y; Shimizu J; Kimura T; Fukuoka J; Iwamoto Y; Sasaki H; Takeda K; Seto T; Ichinose Y; Nakagawa K; Nakanishi Y;
Ann Oncol; 2015 Feb; 26(2):363-8. PubMed ID: 25403584
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
11. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
Wang Y; Zhang X; Tian D; Han S; Zhang J; Nie J; Dai L; Hu W; Chen X; Ma X; Tian G; Wu D; Zhang Z; Long J; Fang J
Cancer Med; 2023 Feb; 12(3):2303-2311. PubMed ID: 35924403
[TBL] [Abstract][Full Text] [Related]
12. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.
Wang W; Lin G; Hao Y; Guan Y; Zhang Y; Xu C; Wang Q; Wang D; Jiang Z; Cai J; Lou G; Song Z; Zhang Y
Eur J Cancer; 2022 Oct; 174():21-30. PubMed ID: 35970032
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
15. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Observation of Immunotherapy Efficacy and Adverse Effects
in Chinese Patients with Lung Squamous Cell Carcinoma].
Yu J; Wu X; Ma J; Chen X; Li L
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):546-554. PubMed ID: 35899455
[TBL] [Abstract][Full Text] [Related]
19. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38625494
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
